US FDA Approves Cimzia for Treatment of Adults with Active Ankylosing spondylitis
It is fortunate that the US Food and Drug Administration (FDA) have expediently approved UCB’s Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis (AS). This ameliorated development came when FDA successfully issued a Complete Response Letter relating to the supplemental Biologics License Application (sBLA) of Cimzia for the treatment of adults with active axial spondyloarthritis (axSpA). They are also reported that UCB is actively working with the FDA to analyze a potent path forward to bring Cimzia to US patients living with active axSpA.
Not many people know about the Ankylosing Spondylitis, or AS, which is considered to be the chronic inflammatory rheumatic disease of the spine and the most well-recognized subset of axSpA. More over the symptoms of AS could vary with different people sometimes experience back pain and stiffness due to inflammation. It is also further slated to be in fusion of the sacroiliac joints. This acute condition generally starts between 15 and 35 years of age, with prevalence estimated to be .5% of the US population. In conclusion AS is more common in men than in women, with Ankylosing spondylitis having a genetic component associated with the HLA-B27 gene.